STAT3 and hepatocellular carcinoma: Our study unveiled a mechanism about SRI as a tumor promotor, interacting with STAT3, inhibited mitochondrial apoptosis by the NF-κB pathway in HCC (Figure 7), which suggests that SRI maybe considered as a promising therapeutic target for HCC.